Functional study of haplotypes in UGT1A1 promoter to find a novel genetic variant leading to reduced gene expression

Therapeutic Drug Monitoring

Volumn 37, Issue 3, 2015, Pages 369-374

  Shin, Hee Jung ^a   Kim, Jason Yongha ^b   Cheong, Hyun Sub ^c   Na, Han Sung ^a   Shin, Hyoung Doo ^b,c   Chung, Myeon Woo ^a  

^a National Institute of Food and Drug Safety Evaluation   (South Korea)

^b Sogang University   (South Korea)

^c SNP Genetics Inc   (South Korea)

Author keywords

haplotype; promoter; single nucleotide polymorphism; UGT1A1

Indexed keywords

BETA GALACTOSIDASE; GLUCURONOSYLTRANSFERASE 1A1; TRANSCRIPTION FACTOR; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC VARIABILITY; GLUCURONIDATION; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; HUMAN GENOME; LUCIFERASE ASSAY; MIDDLE AGED; NORMAL HUMAN; PHARMACOGENETICS; POPULATION STRUCTURE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; AFRICAN AMERICAN; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; DOWN REGULATION; GENETIC VARIATION; GENETICS;

ADULT; AFRICAN AMERICANS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DOWN-REGULATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84929954097     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000154     Document Type: Article

References (28)

1. Wang LS, Shang JJ, Shi SY, et al. Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage. Eur J Clin Pharmacol. 2013;69: 1113-1120.
2. Manske M, Miott o O, Campino S, et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature. 2012;487:375-379.
3. Reyes M, Rothe HM, Mattar P, et al. Antilip olytic effect of calcimimetics depends on the allelic variant of calcium-sensing receptor gene polymorphism rs1042636 (Arg990Gly). Eur J Hum Genet. 2012;20:480-482.
4. Mackenzie PI, Miners JO, McKinnon R A. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med. 2000;38:889-892.
5. Yamamoto K, Sato H, Fujiyama Y, et al. Contribut ion of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta. 1998;1406:267-273.
6. Sugatani J, Yamakawa K, Yoshinari K, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun. 2002;292:492-497.
7. Gagne JF, Montminy V, Belanger P, et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol. 2002;62: 608-617.
8. Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos.2003;31:108-113.
9. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926.
10. Ki CS, Lee KA, Lee SY, et al. Haplotype structure of the UDPglucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin Chem. 2003;49:2078-2081.
11. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24:2237-2244.
12. Bae JW, Choi CI, Lee JH, et al. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Eur J Clin Pharmacol. 2011;67:39-45.
13. Park WB, Choe PG, Song KH, et al. Genetic factors influencing severe atazanavir-Associated hyperbilirubinemia in a population with low UDP-glu curonosyltransferase 1A1 28 allele frequency. Clin Infect Dis. 2010;51:101-106.
14. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
15. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
16. St ephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
17. Sandelin A, Wasserman WW, Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res. 2004;32:W249-W252.
18. Nakamura A, Nakajima M, Yamanaka H, et al. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos. 2008;36:1461-1464.
19. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gen e predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1388.
20. Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002;12:725-733.
21. Innocenti F,Liu W,Chen P,et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes Pharmacogenet Genomics. 2005, 15, 295-301.
22. Maitland ML, Grimsley C, Kuttab-Boulos H, et al. Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J. 2006;6:52-62.
23. Iolascon A, Faienza MF, Centra M, et al. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Haematologica. 1999;84:106-109.
24. Levesque E, Belanger AS, Harvey M, et al. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecanbased regim ens. J Pharmacol Exp Ther. 2013;345:95-101.
25. Hock H, Orkin SH. Zinc-finger transcription factor Gfi-1: versatile regulator of lymphocytes, neutrophils and hematopoietic stem cells. Curr Opin Hematol. 2006;13:1-6.
26. Tuteja G, Kaestner KH. SnapShot: forkhead transcription factors I. Cell. 2007;130:1160.
27. Tuteja G, Kaestner KH. Forkhead transcription factors II. Cell. 2007; 131:192.
28. Chen G, Ramos E, Adeyemo A, et al. UGT1A1 is a major locus influencing bilirubin levels in African Americans. Eur J Hum Genet. 2012;20:463-468.